Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The US FDA’s Medical Device Postmarket Transformation Initiative

This article was originally published in RAJ Devices

Executive Summary

US manufacturers of medical devices can expect to see increased scrutiny of their postmarketing reports as the US Food and Drug Administration’s Center for Devices and Radiological Health takes action to strengthen its Medical Device Postmarket Transformation Initiative. The initiative, launched in 20061, was designed to increase the ability of CDRH to identify, analyse and act on postmarket information, thereby improving the safety and effectiveness of medical devices and radiation-emitting products. It is focused on execution in four areas: creating a culture of collaboration within CDRH, developing world-class data systems, enhancing risk:benefit communication efforts and collaborating on enforcement strategies and outcomes.

You may also be interested in...


UsernamePublicRestriction

Register

SC092872

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel